IP Verse

Prevention And Treatment Of Synucleinopathic And Amyloidogenic Disease - EP1793855

EP1793855

ELAN PHARMACEUTICALS
Application Number
EP05783732A
Filing Date
Aug 9, 2005
Status
Patent Maintained As Amended
Dec 17, 2021
Grant Date
Jan 19, 2022
External Links
Slate, Register, Google Patents

Bibliography

The patent EP1793855B2 was granted to Elan Pharmaceuticals on Jan 19, 2022 following the initial filing on Aug 9, 2005 under the application number EP05783732A . The current legal status of the patent is Patent Maintained As Amended.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

MATHYS & SQUIREAug 14, 2019ADMISSIBLE

Patent Citations New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePatent NumberPatent Link
DESCRIPTIONUS20030471929-
DESCRIPTIONUS20040984192-
DESCRIPTIONEP0378881
DESCRIPTIONEP0427347
DESCRIPTIONGB2220211
DESCRIPTIONUS2005009150
DESCRIPTIONUS4634664
DESCRIPTIONUS4634666
DESCRIPTIONUS4666829
DESCRIPTIONUS4855283
DESCRIPTIONUS5057540
DESCRIPTIONUS5196512
DESCRIPTIONUS5208036
DESCRIPTIONUS5225539
DESCRIPTIONUS5229490
DESCRIPTIONUS5264618
DESCRIPTIONUS5279833
DESCRIPTIONUS5283185
DESCRIPTIONUS5304489
DESCRIPTIONUS5399346
DESCRIPTIONUS5530101
DESCRIPTIONUS5545806
DESCRIPTIONUS5565332
DESCRIPTIONUS5569825
DESCRIPTIONUS5585089
DESCRIPTIONUS5593970
DESCRIPTIONUS5612486
DESCRIPTIONUS5625126
DESCRIPTIONUS5633425
DESCRIPTIONUS5643576
DESCRIPTIONUS5661016
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS5733743
DESCRIPTIONUS5736142
DESCRIPTIONUS5741957
DESCRIPTIONUS5770429
DESCRIPTIONUS5789650
DESCRIPTIONUS5814318
DESCRIPTIONUS5837242
DESCRIPTIONUS5849992
DESCRIPTIONUS5858657
DESCRIPTIONUS5871907
DESCRIPTIONUS5874299
DESCRIPTIONUS5877218
DESCRIPTIONUS5877397
DESCRIPTIONWO0072876
DESCRIPTIONWO0072880
DESCRIPTIONWO0160794
DESCRIPTIONWO2005013889
DESCRIPTIONWO2005047860
DESCRIPTIONWO9007861
DESCRIPTIONWO9014837
DESCRIPTIONWO9110741
DESCRIPTIONWO9117271
DESCRIPTIONWO9118980
DESCRIPTIONWO9201047
DESCRIPTIONWO9220791
DESCRIPTIONWO9222653
DESCRIPTIONWO9301222
DESCRIPTIONWO9306121
DESCRIPTIONWO9408051
DESCRIPTIONWO9412629
DESCRIPTIONWO9505853
DESCRIPTIONWO9507707
DESCRIPTIONWO9512608
DESCRIPTIONWO9530642
DESCRIPTIONWO9535503
DESCRIPTIONWO9634625
DESCRIPTIONWO9717613
DESCRIPTIONWO9717614
DESCRIPTIONWO9823635
DESCRIPTIONWO9825386
DESCRIPTIONWO9840100
DESCRIPTIONWO9859050
INTERNATIONAL-SEARCH-REPORTUS2002094335
INTERNATIONAL-SEARCH-REPORTUS2002197258
INTERNATIONAL-SEARCH-REPORTWO2004041067
INTERNATIONAL-SEARCH-REPORTWO2005047860
OPPOSITIONEP1572894
OPPOSITIONEP1578253
OPPOSITIONWO03000714
OPPOSITIONWO03045128
OPPOSITIONWO2004041067
OPPOSITIONWO2005047860
OPPOSITIONWO2006020581
SEARCHWO2004041067
SEARCHWO2005013889
SEARCHWO2005047860

Non-Patent Literature (NPL) Citations New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "Antibody Against alpha-Synuclein Looks Safe In Phase 1", Alzforum networking for a cure, (20150331), pages 1 - 7, XP055632584-
OPPOSITION- VOILES et al., "Vesicle Penneabilization by Protofibrillar a.-Synuclein: Implications for the Pathogenesis and Treatment of Parkinson's Disease", Biochemistry, (20010000), vol. 40, no. 26, pages 7812 - 19, XP055632587-
OPPOSITION- WAXMAN et al., "Characterization of antibodies that selectively detect α-synuclein in pathological inclusions", Acta Neuropathol, (20080000), vol. 116, no. 1, pages 37 - 46, XP019628809-
OPPOSITION- DUDA et al., "Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases", Ann Neurol, (20020000), vol. 52, pages 205 - 210, XP002735853
OPPOSITION- TRAN et al., "α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration", Cell Rep, (20140000), vol. 7, no. 6, pages 2054 - 2065, XP055168764
OPPOSITION- MASLIAH et al., "Effects of alpha-synuclein immunization in a mouse model of Parkinsons disease", NEURON", Neuron, (20050000), vol. 46, pages 857 - 868, XP008091682
OPPOSITION- Bennett, "The role of @a-synuclein in neurodegenerative diseases", Pharmacology & Therapeutics, (20050000), vol. 105, no. 3, pages 311 - 331, XP004765148
OPPOSITION- URYU et al., "age dependent synuclein pathology following traumatic brain injury in mice", Exp Neurol, (20030000), vol. 184, pages 214 - 224, XP055632567
OPPOSITION- GIASSON et al., "Neuronal a-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human a-Synuclein", Neuron, (20020000), vol. 34, pages 521 - 533, XP055632422
OPPOSITION- EMADI et al., ""Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.", Biochemistry, (20040000), vol. 43, pages 2871 - 2878, XP002517647
OPPOSITION- CONWAY et al., "Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease", Nat Med, (19980000), vol. 4, no. 11, pages 1318 - 20, XP002283512
OPPOSITION- LASHUEL et al., "The many faces of α-synuclein: from structure and toxicity to therapeutic target DT", Nat Rev Neurosci, (20130000), vol. 14, no. 1, pages 38 - 48, XP055230475
OPPOSITION- MISHIZEN-ERBERZ et al., "Distinct cleavage patterns of normal and pathologic forms of a-synuclein by calpain I in vitro", J Neurochem, (20030000), vol. 86, no. 4, pages 836 - 847, XP002983970
OPPOSITION- SPILLANTINI et al., "a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies", Proc Natl Acad Sci USA, (19980000), vol. 95, pages 6469 - 6473, XP055632419
OPPOSITION- NARHI et al., "Both Familial Parkinson's Disease Mutations Accelerate a-Synuclein Aggregation", J Biol Chem, (19990000), vol. 274, no. 14, pages 9843 - 9846, XP055632571
OPPOSITION- MIAKE et al., "Biochemical Characterization of the Core Structure of a-Synuclein Filaments", J Biol Chem, (20020000), vol. 277, no. 21, pages 19213 - 9, XP055632580
OPPOSITION- GREENBAUM et al., "The E46K Mutation in a-Synuclein Increases Amyloid Fibril Formation", J Biol Chem, (20050000), vol. 280, no. 9, pages 7800 - 7807, XP055632573
OPPOSITION- NORRIS et al., J Biol Chem, (20050000), vol. 280, no. 22, pages 21212 - 21219, XP055632569
OPPOSITION- MASLIAH et al., "Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders", Science, (20000000), vol. 287, pages 1265 - 1269, XP002201745
OPPOSITION- MASLIAH et al., "Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease", PLoS ONE, (20110000), vol. 6, no. 4, page e19338, XP055023042
OPPOSITION- SHAHADUZZAMAN et al., "Anti-Human α-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-α-Synuclein Rat Model of Parkinson’s Disease", PLoS One, (20150000), vol. 10, no. 2, pages 1 - 16, XP055238340
OPPOSITION- LEE et al., "Intravesicular Localization and Exocytosis of a-Synuclein and its Aggregates", J Neurosci, (20050000), vol. 25, no. 25, pages 6016 - 24, XP055632575
OPPOSITION- BAE et al., "Antibody-Aided Clearance of Extracellular -Synuclein Prevents Cell-to-Cell Aggregate Transmission", J Neurosci, (20120000), vol. 32, no. 39, pages 13454 - 69, XP055107975
SEARCH- MASLIAH E ET AL, "Effects of alpha-synuclein immunization in a mouse model of Parkinsons disease", NEURON, CELL PRESS, US, (20050616), vol. 46, no. 6, ISSN 0896-6273, pages 857 - 868, XP008091682 [PX] 4-15,22,23,28,29,39,40 * abstract * * page 864, column L, paragraph 1 - page 865, column L, paragraph 1 * [PY] 1-3,16-21,30-38,41,42
SEARCH- ZHOU C ET AL, "A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, (20041201), vol. 10, no. 6, ISSN 1525-0016, pages 1023 - 1031, XP004651493 [PA] * the whole document *
SEARCH- EMADI SHARAREH ET AL, "Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.", BIOCHEMISTRY 16 MAR 2004, (20040316), vol. 43, no. 10, ISSN 0006-2960, pages 2871 - 2878, XP002517647 [A] * abstract * * page 2872, column L, paragraph 2 * * page 2875, column R, paragraph L - page 2876, column R, paragraph L *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents